eClinical Tech News

Nasus Pharma reported positive interim Phase 2 data for NS002, an intranasal powder formulation of epinephrine for anaphylaxis, demonstrating...

Telix Pharmaceuticals reported unaudited Q4 2025 group revenue of approximately $208 million, up 46% year over year, bringing full-year...

Genmab reported topline Phase 3 results from Epcore DLBCL-1 showing that subcutaneous epcoritamab monotherapy improved progression-free survival versus investigator’s...

Connect has promoted Cait Kelly to Chief Strategy Officer, adding her to a recently restructured executive team as the...

Foghorn Therapeutics has raised $50 million in a premium-priced equity financing expected to close January 13, 2026, extending its...

Immunocore outlined a 2026 agenda centered on scaling Kimmtrak in metastatic uveal melanoma, advancing three registrational melanoma trials, and...

argenx reported unaudited 2025 global product net sales of approximately $4.15 billion, including $1.29 billion in the fourth quarter,...

Foghorn Therapeutics has secured a $50 million equity financing at a 30% premium to market and outlined 2026 objectives...

Teva has secured up to $500 million in development financing from Royalty Pharma to advance its anti–IL-15 monoclonal antibody,...

Immunocore laid out a 2026 agenda centered on expanding its melanoma franchise and advancing its TCR bispecific platform beyond...